AI-Based Mobile Intervention on Medication Non-Adherence and Transition
University of Central Florida
Summary
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
Eligibility
- Age range
- 14–24 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Diagnosed with epilepsy * Currently prescribed anti-seizure medicine (ASMs) * Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) * Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study * Are between 18-24 years old and able to provide informed consent * Ab…
Interventions
- OtherMedilepsy® Chatbot AI-Enhanced
Participants in the intervention group will use the AI-personalized version of the Medilepsy® app, which includes a Smart Chatbot that delivers interactive support based on user-entered data. The chatbot offers personalized prompts, relevant topic suggestions, and adaptive educational content to support epilepsy self-management.
- OtherMedilepsy® Chatbot Standard
Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality. This version includes static prompts and general educational links but does not provide personalized feedback or adaptive interaction.
Locations (2)
- Orlando HealthOrlando, Florida
- University of Central FloridaOrlando, Florida